Detalhe da pesquisa
1.
A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR.
Invest New Drugs
; 38(5): 1483-1494, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32189093
2.
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 76(5): 1025-32, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26420235
3.
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.
Cancer Chemother Pharmacol
; 76(5): 1041-9, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26429709